Advertisement

Topics

Genocea Biosciences Company Profile

14:55 EST 13th December 2018 | BioPortfolio

Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The Company’s proprietary T cell-directed antigen discovery program represents a broad platform with the potential to generate significant novel vaccines for multiple pathogens with high unmet medical need. Genocea is currently developing vaccines for Chlamydia trachomatis (a sexually transmitted disease agent causing an estimated 90 million cases worldwide), Streptococcus pneumoniae (pneumonia is the leading killer of children under the age of five worldwide), Herpes Simplex Virus Type 2 (45 million infected in the US)and Malaria (millions of cases each year) Genocea was recognized by BusinessWeek as one of the “World’s Most Intriguing Startups” for 2009. In 2008, Genocea was selected as “Best Vaccine Startup” at the World Vaccine Congress and was selected one of the 15 most exciting biotech startup companies by FierceBiotech. Genocea is backed by leading investors including Lux Capital Management, Polaris Venture Partners, S.R. One, the corporate venture arm of GlaxoSmithKline, Auriga Partners, Cycad Group, Morningside Ventures and Alexandria Real Estate Equities. Visit www.genocea.com for more information.


News Articles [613 Associated News Articles listed on BioPortfolio]

5 Top Weekly NASDAQ Biotech Stocks: Genocea Up 56.74 Percent

Genocea Biosciences, EyePoint Pharmaceuticals, Trevena, Adamis Pharmaceuticals and KalVista Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index. The post 5 Top Weekly NASDA...

Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q3 2018 Results - Earnings Call Transcript

Cofactor Genomics to Provide Solid Tumor Immune Profiling for Genocea Biosciences

-- Pilot study to evaluate use of Cofactor assay in Genocea’s neoantigen vaccine clinical trial -- Cofactor Genomics, a clinical RNA sequencing and translational assa...

Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion

Illumina, Inc. and Pacific Biosciences announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction....

Genocea to Present at Two September Investor Conferences

CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, pre...

Genocea to Present at Two October Investor Conferences

CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, pr...

Genocea Announces Upcoming Presentations at SITC 2018

Posters showcase ability of ATLAS™ platform to identify neoantigens for inclusion in and exclusion from personalized immunotherapies CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Genocea...

Genocea Reports Second Quarter 2018 Financial and Operating Results

Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial underway ATLAS™ platform continues to stand apart from in silico methods of neoantigen identificationConference call today at 9:00 am ET...

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

Clinical Trials [9 Associated Clinical Trials listed on BioPortfolio]

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A proprietary to...

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Rheumatoid Arthritis

Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment fo...

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Companies [372 Associated Companies listed on BioPortfolio]

Genocea Biosciences

Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The Company’s proprietary T cell-directed antigen disc...

Genocea Biosciences, Inc.

Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell responses help confer protect...

Genocea Biosciences Inc.

Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell response helps confer protect...

Genocea Biosciences, Inc. 

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

More Information about "Genocea Biosciences" on BioPortfolio

We have published hundreds of Genocea Biosciences news stories on BioPortfolio along with dozens of Genocea Biosciences Clinical Trials and PubMed Articles about Genocea Biosciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genocea Biosciences Companies in our database. You can also find out about relevant Genocea Biosciences Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record